Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Biomarin Pharmaceutical Q3 2026 Results: Net Loss of $123M, Loss Widens

BioMarin reported total revenues of $1.02 billion for the third quarter of 2026, a significant increase from $776.1 million in the prior year, though it recorded a net loss of $122.8 million due to higher operating expenses and intangible asset amortization. The company's balance sheet expanded significantly following a $5.07 billion business combination, funded in part by $3.65 billion in new borrowings.

Watch the Biomarin Pharmaceutical Inc earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1,024.6776.1
Profit before tax-131.8-26.3
Net income-122.8-30.7
EPS (diluted, $ a share)$-0.63$-0.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+32.0%
Operating margin-8.0%
Source

10-Q filed with the SEC, NASDAQ: BMRN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Biomarin Pharmaceutical Inc: key numbers

Share price
$57.99Close, Nov 16
Market cap
$11.2B
Shares outstanding
193.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Biomarin Pharmaceutical Inc

All →
4:07 PM ET 8-K
Financial Results

Biomarin Pharmaceutical Financial Results

BioMarin reported third-quarter 2026 financial results, achieving a milestone of over $1 billion in quarterly revenue, a 32% year-over-year increase. Growth was driven by the acquisition of Amicus Therapeutics and strong demand for metabolic and skeletal condition treatments. The company also announced an FDA PDUFA date of May 30, 2027, for the potential expansion of VOXZOGO into hypochondroplasia.

Term
Q3 2026

“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin.”

Alexander Hardy, President and Chief Executive Officer

“As we approach 2027, we are well positioned for our next chapter of growth, including the potential launch of VOXZOGO in hypochondroplasia and the continued execution of our financial and innovation strategy.”

Alexander Hardy, President and Chief Executive Officer
4:23 PM ET 8-K
Business Update

Biomarin Pharmaceutical Business Update

BioMarin disclosed the estimated financial impact of its August 31, 2026, acquisition of Alesta Therapeutics, including a $283 million pre-tax charge for acquired in-process research and development (IPR&D). The acquisition is expected to have a $1.50 unfavorable impact on Q3 2026 EPS and a $1.55 impact on full-year 2026 EPS, with updated full-year guidance to be provided during the Q3 earnings call.

Counterparty
Alesta Therapeutics B.V.
4:16 PM ET 8-K
Licensing Deal

Biomarin Pharmaceutical Licensing Deal with Ascendis Pharma A/S

BioMarin entered into a definitive Settlement and License Agreement with Ascendis Pharma, granting Ascendis a non-exclusive worldwide license to certain patents for the commercialization of TransCon CNP (navepegritide). In exchange, BioMarin will receive royalties of 20% on net sales in the U.S. and 18% in the EU, Brazil, and South Korea through May 2030, while both parties agreed to dismiss all pending patent litigation.

Counterparty
Ascendis Pharma A/S
Term
through May 2030
8:32 AM ET 8-K
Other 8-K Filing

Biomarin Pharmaceutical Other 8-K Filing

BioMarin Pharmaceutical Inc. announced its decision to discontinue the clinical development of VOXZOGO for children with Noonan syndrome. The company cited study feasibility and the current treatment landscape as reasons for the move, noting the decision was not related to safety or efficacy.

9:27 AM ET 8-K
Executive Compensation

Biomarin Pharmaceutical Executive Compensation

BioMarin Pharmaceutical Inc. increased its board size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent director. Dr. Plenge will receive standard non-employee director fees and was granted restricted stock units (RSUs) valued at $400,000, which vest just prior to the company's next annual meeting.

Counterparty
Robert Plenge

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.